According to the Magic Pharmaceutical announcement, the cumulative deviation value of the closing price increase of the company's A-share shares exceeded 20% for three consecutive trading days on August 17, August 18, and August 19, 2026, which is an abnormal fluctuation in stock trading. The cumulative increase in the company's stock price in the past six trading days reached 50.48%. The latest TTM price-earnings ratio was 114.99 times, which is significantly higher than the level of about 53.06 times that of the same industry. The turnover rate reached 33.91% on August 19. There is a risk of irrational speculation and a rapid decline in stock prices. After self-inspection and consultation with the controlling shareholders, there were no important matters that should be disclosed, and there were no major changes in the main business. Revenue in 2025 was 1,952 billion yuan, down 4.71% year on year; after deducting non-net profit of 34.869 million yuan, a year-on-year decrease of 50.97%. Revenue for the first quarter of 2026 was 423 million yuan, down 11.87% year on year; after deducting non-net profit of 126.7772 million yuan, a year-on-year decrease of 15.44%. In addition, the controlling shareholder, the remaining 1.69% of the shares of Zhang Zhijun, will be reduced through a major transaction. The reduction expires on August 25, 2026.

According to the Magic Pharmaceutical announcement, the cumulative deviation value of the closing price increase of the company's A-share shares exceeded 20% for three consecutive trading days on August 17, August 18, and August 19, 2026, which is an abnormal fluctuation in stock trading. The cumulative increase in the company's stock price in the past six trading days reached 50.48%. The latest TTM price-earnings ratio was 114.99 times, which is significantly higher than the level of about 53.06 times that of the same industry. The turnover rate reached 33.91% on August 19. There is a risk of irrational speculation and a rapid decline in stock prices. After self-inspection and consultation with the controlling shareholders, there were no important matters that should be disclosed, and there were no major changes in the main business. Revenue in 2025 was 1,952 billion yuan, down 4.71% year on year; after deducting non-net profit of 34.869 million yuan, a year-on-year decrease of 50.97%. Revenue for the first quarter of 2026 was 423 million yuan, down 11.87% year on year; after deducting non-net profit of 126.7772 million yuan, a year-on-year decrease of 15.44%. In addition, the controlling shareholder, the remaining 1.69% of the shares of Zhang Zhijun, will be reduced through a major transaction. The reduction expires on August 25, 2026.